Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028504 | 1.00 | CCR1 (0.41) | CCR1CNR1CNR2PYGLCAPN1 | |
| SCHEMBL24444088 | 0.90 | CCR1 (0.40) | CCR1CNR1CNR2PYGL | |
| SCHEMBL24444089 | 0.90 | CCR1 (0.40) | CCR1CNR1CNR2PYGL | |
| SCHEMBL20028172 | 0.85 | PYGL (0.41) | CCR1CNR1CNR2PYGLCAPN1 | |
| SCHEMBL20027982 | 0.84 | CAPN1 (0.57) | CAPN1 | |
| SCHEMBL21854036 | 0.84 | CAPN1 (0.57) | CAPN1 | |
| SCHEMBL20027494 | 0.83 | HDAC8 (0.43) | CCR1CNR1CNR2PYGL | |
| SCHEMBL20027892 | 0.81 | PYGL (0.44) | CCR1CNR1CNR2PYGL | |
| SCHEMBL20028168 | 0.81 | PYGL (0.44) | CCR1CNR1CNR2PYGL | |
| SCHEMBL22896469 | 0.79 | CAPN1 (0.51) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CCR1 4696/4885CNR1 3073/4885CNR2 3409/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CCR1 4788/4885CNR1 2961/4885CNR2 2995/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CCR1 4696/4885CNR1 3073/4885CNR2 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.